Kronos Worldwide, Inc. KRO reported a third-quarter 2025 net loss of $37 million or 32 cents per share. This compares unfavorably to profits of $71.8 million, or 62 cents per share in the year-ago ...

DALLAS (AP) — DALLAS (AP) — Kronos Worldwide Inc. (KRO) on Thursday reported a loss of $37 million in its third quarter. On a per-share basis, the Dallas-based company said it had a loss of 32 cents.

Noble Audio has launched its new flagship in-ear monitor, the Kronos, now in full production after first appearing as a limited-edition 10th anniversary model. It is based on the Chronicle design but ...

The new Kronos IEMs from have nine drivers and a six-way crossover but an impedance of less than 35Ω. Noble Audio has announced the launch of its latest pair of flagship in-ear monitors. The Kronos ...

Today (July 16) marks the 80th anniversary of the Trinity test, during which a team of U.S. scientists led by J. Robert Oppenheimer detonated the world’s first atomic bomb in the deserts of New Mexico ...

(RTTNews) - Kronos Bio (KRON) has entered into a definitive merger agreement with Concentra Biosciences, LLC, whereby Concentra will acquire Kronos Bio for $0.57 in cash per share of Kronos Bio common ...

Performances in N.Y.C. Advertisement Supported by The venerable quartet returned to Zankel Hall with a typically eclectic program and a newfound emotional intensity. By Corinna da Fonseca-Wollheim The ...

Antonia Haynes is a Game Rant writer who resides in a small seaside town in England where she has lived her whole life. Beginning her video game writing career in 2014, and having an avid love of ...

Kronos Bio, a San Mateo biotech company, is losing millions of dollars a month and recently had to discontinue its sole clinical-stage compound because of adverse side effects. Now, the company is ...

Kronos Q324 sales volumes soared, offsetting flat TiO2 selling prices to deliver +22% YoY revenue growth along with improved profitability. The company faces high growth expectations as it integrates ...

On the heels Kronos Bio’s decision to can its last remaining clinical asset earlier this month, the company said it would roll out “significant expense reduction strategies” to buy itself more time.

FOR DECADES string-quartet recitals conjured an image of men in tailcoats demurely playing staid classical works in a concert hall. But the Kronos Quartet took to the stage in San Francisco on June ...